Global Immunoglobulins Market Segmentation, By Application (Hypogammaglobulinemia, Chronic Inflammatory Demyelinating Polyneuropathy, Immunodeficiency Disease, Myasthenia Gravis, Multifocal Motor Neuropathy, Idiopathic Thrombocytopenic Purpura, Inflammatory Myopathies, Specific Antibody Deficiency, Guillain‐Barré Syndrome, Others), Product (IgA, IgG, IgM, IgE, IgD), Mode of Delivery (Intravenous, Subcutaneous) – Industry Trends and Forecast to 2032
Immunoglobulins Market Analysis
The global immunoglobulins market is expected to grow rapidly due to the rise in the incidence of autoimmune illnesses,. According to the Immune Deficiency Foundation (IDF), primary immunodeficiency affected 83 out of every 100,000 people in North America in 2017, resulting in 350 hereditary disorders. As the world's geriatric population grows, so does the demand for more effective immunological therapies.
Global Immunoglobulins Market Size
Global immunoglobulins market size was valued at USD 16.06 billion in 2024 and is projected to reach USD 27.69 billion by 2032, with a CAGR of 7.05% during the forecast period of 2025 to 2032.
Report Scope and Market Segmentation
|
Attributes
|
Immunoglobulins Key Market Insights
|
|
Segmentation
|
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
|
|
Key Market Players
|
Baxter (US), Biotest AG. (Germany), China Biologic Products Holdings, Inc. (China), CSL Limited (Australia), Grifols, S.A. (Spain), Kedrion S.p.A (Italy), Octapharma (Switzerland), GREEN CROSS CORP (South Korea), Coram LLC (US), Momenta Pharmaceuticals (US), Option Care Enterprises, Inc. (US), ADMA Biologics, Inc. (US), Gentian Diagnostics AS (Norway), Mabtech (Sweden), J. Mitra & Co. Pvt. Ltd (India), Cygnus Technologies (NC), Kamada Pharmaceuticals (Israel), HAFFKINE BIO-PHARMACEUTICAL CORPORATION LTD (India), Kedrion Biopharma Inc. (US), Hualan Biological Engineering Inc. (Henan)
|
|
Market Opportunities
|
|
Immunoglobulins Market Definition
Immunoglobulins, often known as antibodies, are a type of glycoprotein molecule produced by plasma or white blood cells (WBCs). They are found in the immune system's serum and cells and work like antibodies by identifying and binding antigens, such as bacteria or viruses, and assisting in their elimination. Their tests aid in the diagnosis of immunodeficiencies, allergies, and autoimmune diseases such as juvenile idiopathic arthritis, lupus, and celiac disease, among others. Immunoglobulins are classified into several classes based on biological characteristics, structure, target specificity, and distribution.
Immunoglobulins Market Dynamics
Drivers
- Increasing prevalence of chronic and autoimmune diseases
The rise in chronic inflammatory demyelinating polyneuropathy (CIDP), hypogammaglobulinemia, and other illnesses is projected to drive market expansion. One of the key drivers of market expansion is the rising number of patients with medical illnesses such as multiple myeloma, Waldenstrom macroglobulinemia, and autoimmune disorders.
- Rise in the prevalence of sedentary lifestyle
The market is also benefiting from the growing prevalence of sedentary lifestyle. Individuals are increasingly consuming fast food as a result of increased urbanization and stressful lifestyles.
Furthermore, the growing geriatric population will act as major factor influencing the growth of immunoglobulins market. Along with this, increasing awareness about early diagnosis and rising level of disposable income are the driving factors accelerating the growth of the immunoglobulins market. Also, increasing expenditure on healthcare infrastructure and increasing preferences for personalized medicines are the major market drivers that will further escalate the growth of immunoglobulins market.
Opportunities
- Increase in the number of research and development activities
Moreover, the market's growth is fueled by an increase in the number of research and development activities which will further provide beneficial opportunities for the immunoglobulins market growth.
Moreover, rising investment for the development of advanced technologies and an increase in the number of emerging markets will provide beneficial opportunities for the immunoglobulins market growth during the forecast period.
Restraints/Challenges
On the other hand, the high cost associated with immunoglobulins will obstruct the growth rate of market. The dearth of skilled professionals and rising risk of side effects linked with the use of immunoglobulin will challenge the immunoglobulins market. Additionally, impact of COVID-19 on supply chain and introduction of alternative technology will act as restrain and further impede the growth rate of market during the forecast period of 2025-2032.
This immunoglobulins market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the immunoglobulins market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Immunoglobulins Market Scope
The immunoglobulins market is segmented on the basis of product, applications and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Application
- Hypogammaglobulinemia
- Chronic Inflammatory Demyelinating Polyneuropathy
- Immunodeficiency Disease
- Myasthenia Gravis
- Multifocal Motor Neuropathy
- Idiopathic Thrombocytopenic Purpura
- Inflammatory Myopathies
- Specific Antibody Deficiency
- Guillain-Barré Syndrome
- Others
Product
- IgA
- IgG
- IgM
- IgE
- IgD
Mode of Delivery
- Intravenous
- Subcutaneous
Immunoglobulins Market Regional Analysis
The immunoglobulins market is analyzed and market size insights and trends are provided by country, product, applications and end user as referenced above.
The countries covered in the immunoglobulins market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the immunoglobulins market because of the well-established healthcare infrastructure and incidences of largest plasma production facilities in this region. Additionally, increasing adoption in advanced countries will flourish the market's growth rate in this region.
Asia-Pacific is expected to grow during the forecast period during the forecast period of 2025 to 2032 due to rising penetration of immunoglobulins and increasing in the alertness in this region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Immunoglobulins Market Share
The Immunoglobulins market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to immunoglobulins market.
Immunoglobulins Market Leaders Operating in the Market Are:
- Baxter (US)
- Biotest AG. (Germany)
- China Biologic Products Holdings, Inc. (China)
- CSL Limited (Australia)
- Grifols, S.A. (Spain)
- Kedrion S.p.A (Italy)
- Octapharma (Switzerland)
- GREEN CROSS CORP (South Korea)
- Coram LLC (US)
- Momenta Pharmaceuticals (US)
- Option Care Enterprises, Inc. (US)
- ADMA Biologics, Inc. (US)
- Gentian Diagnostics AS (Norway)
- Mabtech (Sweden)
- J. Mitra & Co. Pvt. Ltd (India)
- Cygnus Technologies (NC)
- Kamada Pharmaceuticals (Israel)
- HAFFKINE BIO-PHARMACEUTICAL CORPORATION LTD (India)
- Kedrion Biopharma Inc. (US)
- Hualan Biological Engineering Inc. (Henan)
Latest Developments in Immunoglobulins Market
- In May 2021, Octapharma USA's investigational new drug (IND) application for a phase three clinical trial on the efficacy and safety of Octagam 10 percent [Immune Globulin Intravenous (Human)] therapy in COVID-19 patients with severe disease progression was authorized by the US Food and Drug Administration (FDA).
SKU-